Drug Information

Drug General Information
Drug ID
D0PL4F
Former ID
DNC006893
Drug Name
GW-3965
Drug Type
Small molecular drug
Indication Discovery agent Investigative [539799]
Structure
Download
2D MOL

3D MOL
Formula
C33H31ClF3NO3
InChI
InChI=1S/C33H31ClF3NO3/c34-32-27(15-8-17-30(32)33(35,36)37)22-38(18-9-19-41-28-16-7-10-24(20-28)21-31(39)40)23-29(25-11-3-1-4-12-25)26-13-5-2-6-14-26/h1-8,10-17,20,29H,9,18-19,21-23H2,(H,39,40)
InChIKey
NAXSRXHZFIBFMI-UHFFFAOYSA-N
PubChem Compound ID
447905
PubChem Substance ID
829748, 7885550, 10300132, 14911410, 17396621, 26755460, 36889920, 46519987, 53787809, 57404840, 78372800, 85788706, 92728670, 93578094, 103249137, 104638678, 124892359, 127337902, 127337903, 127337904, 134344098, 135325764, 135650333, 136367927, 136946547, 137183401, 139769446, 144115385, 144116041, 151995567, 152258261, 160647097, 171578606, 172650060, 172659554, 179317066, 185989924, 198939615, 223397282, 223445164, 223943816, 228248894, 241080729, 247228919, 252215521
Target and Pathway
Target(s) Oxysterols receptor LXR-beta Target Info Inhibitor [529781]
Oxysterols receptor LXR-alpha Target Info Inhibitor [529781]
KEGG Pathway PPAR signaling pathway
Non-alcoholic fatty liver disease (NAFLD)
Hepatitis C
Pathway Interaction Database RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptor
Reactome Nuclear Receptor transcription pathway
WikiPathways SREBP signalling
Nuclear ReceptorsWP299:Nuclear Receptors in Lipid Metabolism and Toxicity
Nuclear Receptors Meta-Pathway
PPAR Alpha Pathway
Liver X Receptor Pathway
Adipogenesis
SREBF and miR33 in cholesterol and lipid homeostasis
Nuclear Receptors
References
Ref 539799(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2754).
Ref 529781J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.